NEW YORK (GenomeWeb News) – NewBridge Pharmaceuticals today announced an agreement to offer Verinata Health's non-invasive prenatal tests in the Middle East and surrounding areas.

Under the exclusive agreement, NewBridge will offer Verinata's Verifi test in the Middle East, Africa, Turkey, and Caspian regions. Financial terms of the deal were not disclosed.

Based in Dubai, United Arab Emirates, NewBridge is a specialty therapeutics firm that commercializes pharmaceuticals, biologics, diagnostics, and medical devices in the Middle East and neighboring areas.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.